Vyome Holdings HIND

NASDAQ HIND

$2.06 -0.03 (-1.44%)

As of: Sep 9, 2026 · 3:59 PM EDT

Key Stats

Market Cap14.46 Mn

P/E-1.21

P/S111.46

Div. Yield0.00

Revenue Growth (1y) (Qtr)-46.04

Add ratio to table…

About

Vyome Holdings, Inc. is a clinical stage specialty pharmaceutical company focused on developing therapeutic candidates for immune inflammatory and rare diseases of unmet need, leveraging its United States and India innovation corridor. Its lead program, VT-1953, is a topical gel being developed to treat malodor and pain associated with malignant fungating wounds in advanced cancer patients. The company also advances VT-1908, an ophthalmic drop for steroid sparing anterior…

The company generates revenue primarily through licensing agreements and royalty payments from Sun Pharma Laboratories Limited for its antifungal products sold in India, including net service fees, milestone payments, and a 5% royalty on net sales. It has not yet recorded product sales revenue from its biotechnology pipeline, as none of those candidates have received regulatory approval.

The company operates through the following segments: biotechnology and pharmaceutical products.

Biotechnology: This segment includes the company's clinical stage programs such as VT-1953 for malignant fungating wounds, VT-1908 for steroid sparing anterior uveitis, and VB-1953 for inflammatory acne, focusing on drug development, preclinical and clinical studies, and regulatory advancement.
Pharmaceutical: This segment comprises the legacy antifungal business based on the Molecular Replacement Therapy platform, including a dandruff lotion and shampoo commercialized in India via a licensing and marketing agreement with Sun Pharma, and the development and licensing of Luliconazole cream for skin fungal diseases.

Vyome Holdings, Inc. occupies a niche position in the immune inflammatory and rare disease therapeutic landscape, competing with larger pharmaceutical firms such as Eli Lilly and Bausch Health, as well as specialized biotech companies like Tarsier Pharma and Eyepoint Pharmaceuticals. Its competitive advantages stem from its United States and India collaboration, a differentiated drug repurposing strategy that reduces development time and cost, a robust intellectual property portfolio with patents extending to 2044, and access to clinical trial sites in both the United States and India.

The company's current customer base consists chiefly of Sun Pharma Laboratories Limited, which distributes its antifungal products in India under their licensing agreement. While its biotechnology segment has not yet generated commercial sales, it anticipates serving patients, hospitals, and healthcare providers upon regulatory approval of its pipeline candidates.

Investment Thesis

▲ Bull case

Vyome’s lead asset VT-1953 has demonstrated compelling Phase 2 efficacy in malignant fungating wounds with statistically significant improvements in malodor and pain, supported by strong p-values and clinically meaningful patient-reported outcomes, which positions it as a first-in-class therapy addressing a condition with no FDA-approved treatments and a total addressable U.S. market estimated at USD 2.2 billion by independent analysts Destum Partners. This strong clinical validation, combined with the recent Orphan Drug Designation filing, provides a clear regulatory pathway to market exclusivity and potential peak annual net sales of USD 600 million, creating a substantial near-term value inflection as the company advances toward pivotal studies and interim Phase 3 results expected in mid-2027. The clean capital structure with no debt and disciplined capital allocation, coupled with successful funding of the Phase 3 study via the ATM facility at minimal dilution, ensures sufficient runway to execute on value-creating milestones without compromising shareholder interests, reinforcing confidence in management’s ability to deliver on long-term value creation.
The strategic licensing agreement with Impetis Biosciences for selective JAK 1/3 and JAK1 inhibitors represents a hidden catalyst that expands Vyome’s pipeline beyond VT-1953 into large immuno-inflammatory markets, with the JAK inhibitor sector projected to grow from USD 23.56 billion in 2025 to USD 56.78 billion by 2030 at a 19.5% CAGR, offering a non-dilutive, commercialization-tied opportunity to leverage the US-India innovation corridor for capital-efficient development. This asset diversification reduces reliance on a single program while tapping into high-growth therapeutic areas, and management’s emphasis on maintaining focus on VT-1953 while advancing these assets through partnership structures signals disciplined execution that could unlock multiple value inflection points over time, particularly as the company builds its platform spanning the US-India innovation corridor.
Vyome’s presentation of VT-1953 data at the prestigious 2026 AACR Annual Meeting, where results were highlighted for their statistical significance and clinical relevance, serves as an underappreciated validation of scientific credibility and regulatory readiness, especially given the company’s stated intent to engage the FDA in Q2 2026 on pivotal study design. The ability to present at such a high-profile oncology conference underscores growing external recognition of the asset’s potential, and combined with the preclinical success of VT-1908 in uveitis — a condition with a $3 billion U.S. market opportunity by 2032 — demonstrates a broader platform capability in immuno-inflammatory diseases that could generate additional value inflection points beyond the lead program, all while maintaining a hyper cost-efficient operational model.

Vyome’s lead asset VT-1953 has demonstrated compelling Phase 2 efficacy in malignant fungating wounds with statistically significant improvements in malodor and pain, supported by strong p-values and clinically meaningful patient-reported outcomes, which positions it as a first-in-class therapy addressing a condition with no FDA-approved treatments and a total addressable U.S. market estimated at USD 2.2 billion by independent analysts Destum Partners. This strong clinical validation, combined with the recent Orphan Drug Designation filing, provides a clear regulatory pathway to market exclusivity and potential peak annual net sales of USD 600 million, creating a substantial near-term value inflection as the company advances toward pivotal studies and interim Phase 3 results expected in mid-2027. The clean capital structure with no debt and disciplined capital allocation, coupled with successful funding of the Phase 3 study via the ATM facility at minimal dilution, ensures sufficient runway to execute on value-creating milestones without compromising shareholder interests, reinforcing confidence in management’s ability to deliver on long-term value creation.
The strategic licensing agreement with Impetis Biosciences for selective JAK 1/3 and JAK1 inhibitors represents a hidden catalyst that expands Vyome’s pipeline beyond VT-1953 into large immuno-inflammatory markets, with the JAK inhibitor sector projected to grow from USD 23.56 billion in 2025 to USD 56.78 billion by 2030 at a 19.5% CAGR, offering a non-dilutive, commercialization-tied opportunity to leverage the US-India innovation corridor for capital-efficient development. This asset diversification reduces reliance on a single program while tapping into high-growth therapeutic areas, and management’s emphasis on maintaining focus on VT-1953 while advancing these assets through partnership structures signals disciplined execution that could unlock multiple value inflection points over time, particularly as the company builds its platform spanning the US-India innovation corridor.
Vyome’s presentation of VT-1953 data at the prestigious 2026 AACR Annual Meeting, where results were highlighted for their statistical significance and clinical relevance, serves as an underappreciated validation of scientific credibility and regulatory readiness, especially given the company’s stated intent to engage the FDA in Q2 2026 on pivotal study design. The ability to present at such a high-profile oncology conference underscores growing external recognition of the asset’s potential, and combined with the preclinical success of VT-1908 in uveitis — a condition with a $3 billion U.S. market opportunity by 2032 — demonstrates a broader platform capability in immuno-inflammatory diseases that could generate additional value inflection points beyond the lead program, all while maintaining a hyper cost-efficient operational model.

▼ Bear case

Despite positive Phase 2 results for VT-1953, the company remains pre-revenue with minimal Q1 2026 revenue of only USD 31,591, reflecting limited commercial traction and continued dependence on fundraising to sustain operations, as evidenced by a net loss of USD 985,521 for the quarter and an operating loss of USD 1,129,940, which raises concerns about the timing and sufficiency of cash runway even after funding the Phase 3 study, particularly given the history of significant operating expenses — including USD 2,965,808 for the full year 2025 — and the inherent risk that clinical delays or unfavorable Phase 3 outcomes could rapidly erode the current cash position of USD 8,795,783 without generating meaningful revenue in the near term.
The Orphan Drug Designation application for VT-1953, while presented as a key milestone, does not guarantee approval, and the company has not disclosed any substantive engagement with the FDA beyond the filing, creating uncertainty around the timeline and likelihood of securing the associated benefits such as 7 years of market exclusivity and tax credits; moreover, the reliance on third-party valuations from Destum Partners — estimating a post-Phase 3 rNPV of USD 1 billion — introduces significant estimation risk, as these projections assume successful trial outcomes, favorable pricing, and market penetration that are far from guaranteed in a rare disease setting with complex reimbursement dynamics and no current standard of care to benchmark against.
Vyome’s expansion into JAK inhibitor assets via the Impetis license, while strategically appealing, introduces execution complexity and diversion risk, as the company acknowledges its immediate focus remains on VT-1953, yet the resources required to advance preclinical candidates into clinical development — even through non-dilutive pathways — still demand scientific, regulatory, and manufacturing bandwidth that could strain a lean organization, especially given the lack of disclosed milestones or timelines for the JAK programs and the competitive, crowded landscape of JAK inhibitors where differentiation and clinical success are uncertain despite preclinical promises from Impetis.

Despite positive Phase 2 results for VT-1953, the company remains pre-revenue with minimal Q1 2026 revenue of only USD 31,591, reflecting limited commercial traction and continued dependence on fundraising to sustain operations, as evidenced by a net loss of USD 985,521 for the quarter and an operating loss of USD 1,129,940, which raises concerns about the timing and sufficiency of cash runway even after funding the Phase 3 study, particularly given the history of significant operating expenses — including USD 2,965,808 for the full year 2025 — and the inherent risk that clinical delays or unfavorable Phase 3 outcomes could rapidly erode the current cash position of USD 8,795,783 without generating meaningful revenue in the near term.
The Orphan Drug Designation application for VT-1953, while presented as a key milestone, does not guarantee approval, and the company has not disclosed any substantive engagement with the FDA beyond the filing, creating uncertainty around the timeline and likelihood of securing the associated benefits such as 7 years of market exclusivity and tax credits; moreover, the reliance on third-party valuations from Destum Partners — estimating a post-Phase 3 rNPV of USD 1 billion — introduces significant estimation risk, as these projections assume successful trial outcomes, favorable pricing, and market penetration that are far from guaranteed in a rare disease setting with complex reimbursement dynamics and no current standard of care to benchmark against.
Vyome’s expansion into JAK inhibitor assets via the Impetis license, while strategically appealing, introduces execution complexity and diversion risk, as the company acknowledges its immediate focus remains on VT-1953, yet the resources required to advance preclinical candidates into clinical development — even through non-dilutive pathways — still demand scientific, regulatory, and manufacturing bandwidth that could strain a lean organization, especially given the lack of disclosed milestones or timelines for the JAK programs and the competitive, crowded landscape of JAK inhibitors where differentiation and clinical success are uncertain despite preclinical promises from Impetis.

Segments Breakdown of Revenue (2025)

Peer group

Peer Comparison

Companies in the Biotechnology

S.No.	Ticker	Company	match	Market Cap	P/E	P/S	Total Debt (Qtr)
1	AMGN	Amgen Inc	primary	211.73 Bn	24.22	5.56	62.75 Bn
2	GILD	Gilead Sciences, Inc.	primary	180.92 Bn	-62.49	5.94	28.66 Bn
3	VRTX	Vertex Pharmaceuticals Inc / Ma	primary	132.16 Bn	30.00	10.50	-
4	REGN	Regeneron Pharmaceuticals, Inc.	primary	82.89 Bn	19.15	5.34	1.99 Bn
5	ARGX	Argenx Se	primary	61.41 Bn	35.80	11.75	-
6	MRNA	Moderna, Inc.	primary	53.99 Bn	-17.13	24.23	0.59 Bn
7	ALNY	Alnylam Pharmaceuticals, Inc.	primary	34.48 Bn	44.51	7.18	-
8	BIIB	Biogen Inc.	primary	31.15 Bn	37.32	3.11	8.09 Bn

Vyome Holdings HIND

About

Investment Thesis

Product and Service Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password